[Influence of ACE inhibitor spirapril on left ventricular hypertrophy].

Article Details

Citation

Copy to clipboard

Arend U, Albrecht S, Meisel E, Schmidt J

[Influence of ACE inhibitor spirapril on left ventricular hypertrophy].

Fortschr Med Orig. 2002 Dec 5;120(4):147-50.

PubMed ID

12613273 [ View in PubMed

]

Abstract

BACKGROUND: In view of the prevalence of left ventricular hypertrophy (LVH) in patients with essential hypertension, (15-30%), with an increased risk (2-4 x) of developing myocardial infarction, heart failure or malignant arrhythmia, possibly even leading to sudden cardiac death, effective reversal of LVH is a major aim of treatment. For this purpose, angiotensin-converting enzyme (ACE) inhibitors have proved to be most suitable. METHOD: In an open bicentric study involving 37 hypertensive patients with LVH confirmed by echocardiography, the effect of spirapril in reversing the left ventricular mass index (LVMI) and diastolic left ventricular wall thickness was investigated after 3 and 6 months. RESULTS: The LVMI decreased by 14.7% after 3, and by 27.3% after 6 months, irrespective of whether spirapril was given alone or in addition to other antihypertensive pre-medication. The results may be due to the proven 24-hour effect of spirapril in conjunction with the very long half-life.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Spirapril	Angiotensin-converting enzyme	Protein	Humans	Yes	Inhibitor	Details